Current evidence for a genetic modulation of the response to analgesics

Pain

Volumn 121, Issue 1-2, 2006, Pages 1-5

  Lötsch, Jörn ^a   Geisslinger, Gerd ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; CARFENTANIL; CATECHOL METHYLTRANSFERASE; CODEINE; CYTOCHROME P450 2D6; GLYCOPROTEIN P; MELANOCORTIN 1 RECEPTOR; MORPHINE; MU OPIATE RECEPTOR;

CATALYSIS; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; GENE DUPLICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; NONHUMAN; PAIN ASSESSMENT; PHARMACOGENOMICS; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANALGESICS; ANIMALS; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP2D6; HUMANS; P-GLYCOPROTEIN; PAIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RECEPTOR, MELANOCORTIN, TYPE 1; RECEPTORS, OPIOID, MU;

EID: 32944456152     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.01.010     Document Type: Review

References (30)

1. Baar C, Laugsand E, Rakvag TN, Klepstad P, Dale O, Kaasa S, et al. Genetic variation in the gene for P-glycoprotein: implications for the clinical efficacy of morphine. Abstract 11th World Congress of Pain. International Association for the Study of Pain. Program No. 1073-P515; 2005.
2. A. Berthele, S. Platzer, B. Jochim, H. Boecker, A. Buettner, and B. Conrad COMT Val108/158Met genotype affects the mu-opioid receptor system in the human brain: evidence from ligand-binding, G-protein activation and preproenkephalin mRNA expression Neuroimage 28 2005 185 193
3. A. Beyer, T. Koch, H. Schroder, S. Schulz, and V. Höllt Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor J Neurochem 89 2004 553 560
4. C. Bond, K.S. LaForge, M. Tian, D. Melia, S. Zhang, and L. Borg Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction Proc Natl Acad Sci USA 95 1998 9608 9613
5. Y. Caraco, Y. Maroz, and E. Davidson Variability in alfentanil analgesia maybe attributed to polymorphism in the mu-opiod receptor gene Clin Pharmacol Ther 69 2001 p63
6. Y. Caraco, J. Sheller, and A.J. Wood Pharmacogenetic determination of the effects of codeine and prediction of drug interactions J Pharmacol Exp Ther 278 1996 1165 1174
7. L. Collart, C. Luthy, C. Favario-Constantin, and P. Dayer Duality of the analgesic effect of tramadol in humans Schweiz Med Wochenschr 123 1993 2241 2243
8. M.L. Dahl, I. Johansson, L. Bertilsson, M. Ingelman-Sundberg, and F. Sjoqvist Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis J Pharmacol Exp Ther 274 1995 516 520
9. P. Dalen, C. Frengell, M.L. Dahl, and F. Sjoqvist Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine Ther Drug Monit 19 1997 543 544
10. K. Eckhardt, S. Li, S. Ammon, G. Schanzle, G. Mikus, and M. Eichelbaum Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation Pain 76 1998 27 33
11. Y. Gasche, Y. Daali, M. Fathi, A. Chiappe, S. Cottini, and P. Dayer Codeine intoxication associated with ultrarapid CYP2D6 metabolism N Engl J Med 351 2004 2827 2831
12. S. Hoffmeyer, O. Burk, O. von Richter, H.P. Arnold, J. Brockmöller, and A. Johne Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci USA 97 2000 3473 3478
13. P. Klepstad, T.T. Rakvag, S. Kaasa, M. Holthe, O. Dale, and P.C. Borchgrevink The 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease Acta Anaesthesiol Scand 48 2004 1232 1239
14. J. Lötsch, C. Skarke, S. Grösch, J. Darimont, H. Schmidt, and G. Geisslinger The polymorphism A118G of the human mu-opioid receptor gene decreases the clinical activity of morphine-6-glucuronide but not that of morphine Pharmacogenetics 12 2002 3 9
15. J. Lötsch, C. Skarke, J. Liefhold, and G. Geisslinger Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives Clin Pharmacokinet 43 2004 983 1013
16. J. Lötsch, C. Skarke, H. Schmidt, M. Rohrbacher, U. Hofmann, and M. Schwab Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites Clin Pharmacol Ther 79 2006 35 48
17. J. Lötsch, C. Skarke, J. Wieting, B. Oertel, H. Schmidt, and J. Brockmöller Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action Clin Pharmacol Ther 79 2006 72 89
18. J. Lötsch, M. Zimmermann, J. Darimont, C. Marx, R. Dudziak, and C. Skarke Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity? Anesthesiology 97 2002 814 819
19. J.S. Mogil, J. Ritchie, S.B. Smith, K. Strasburg, L. Kaplan, and M.R. Wallace Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans J Med Genet 42 2005 583 587
20. J.S. Mogil, S.G. Wilson, E.J. Chesler, A.L. Rankin, K.V. Nemmani, and W.R. Lariviere The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans Proc Natl Acad Sci USA 100 2003 4867 4872
21. L. Poulsen, L. Arendt-Nielsen, K. Brosen, and S.H. Sindrup The hypoalgesic effect of tramadol in relation to CYP2D6 Clin Pharmacol Ther 60 1996 636 644
22. T.T. Rakvag, P. Klepstad, C. Baar, T.M. Kvam, O. Dale, and S. Kaasa The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients Pain 116 2005 73 78
23. R. Romberg, E. Olofsen, E. Sarton, J. den Hartigh, P.E. Taschner, and A. Dahan Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences Anesthesiology 100 2004 120 133
24. R.R. Romberg, E. Olofsen, H. Bijl, P.E. Taschner, L.J. Teppema, and E.Y. Sarton Polymorphism of mu-opioid receptor gene (OPRM1:c.118A > G) does not protect against opioid-induced respiratory depression despite reduced analgesic response Anesthesiology 102 2005 522 530
25. C. Sachse, J. Brockmöller, S. Bauer, and I. Roots Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences Am J Hum Genet 60 1997 284 295
26. S.H. Sindrup, K. Brosen, P. Bjerring, L. Arendt-Nielsen, U. Larsen, and H.R. Angelo Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine Clin Pharmacol Ther 48 1990 686 693
27. C. Skarke, J. Darimont, H. Schmidt, G. Geisslinger, and J. Lötsch Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers Clin Pharmacol Ther 73 2003 107 121
28. U.M. Stamer, K. Lehnen, F. Hothker, B. Bayerer, S. Wolf, and A. Hoeft Impact of CYP2D6 genotype on postoperative tramadol analgesia Pain 105 2003 231 238
29. Y. Zhang, D. Wang, A.D. Johnson, A.C. Papp, and W. Sadee Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G J Biol Chem 2005
30. J.K. Zubieta, M.M. Heitzeg, Y.R. Smith, J.A. Bueller, K. Xu, and Y. Xu COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor Science 299 2003 1240 1243